drugset / Trial / NCT04706286

Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393

NCT04706286

Phase 1 Unknown 26 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

A Clinical Trial to evaluate the Pharmacokinetics and safety of CKD-393 0.5/100/1000 mg under fed condition

Timeline

Start
2021-02-18
Primary completion
2021-03-29
Completion
2021-04-05

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-393 Unknown Oral
Subject D150 Unknown 1000 mg Oral
Subject D759 Unknown 100 mg Oral
Subject Lobeglitazone Small molecule 0.5 mg Oral